Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 10;12:804387. doi: 10.3389/fimmu.2021.804387

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Huang, Liang, Zhang, Tian, Cong, Wu, Zhang, Gao, Li, Chen, Zhang, Dong, Wan, He, Dai, Li and Xiong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The prediction of the worse outcome for lung cancer patients infected with SARS-CoV-2. Lung cancer patients infected with SARS-CoV-2 may have a worse outcome because SARS-CoV-2-induced ACE2 and NPC1 elevation may have a negative influence on the immune response of LUSC and CD8+T infiltration of LUAD, and negatively affect the sensitivity of anti-cancer drugs including Ifosfamide, Paclitaxel, and Vinorelbine. miR-760 may have the potential to serve as a treatment and intervention target for SARS-CoV-2 because of its targeted inhibition effect on ACE2.